We report the genomic organization of a novel human gene mapped to chromosome 6p21, encoding a putative glycosylphosphatidylinositol (GPI) anchored protein containing a MAM (meprin, A5 antigen, protein tyrosine phosphatase m) domain, that we have termed as GPIM (GPI and MAM) protein. GPIM gene consists of an 8.9 kb transcript composed of 17 coding exons spanning about 65.5 kb of genomic DNA. The deduced polypeptide consists of 955 amino acids and exhibits structural features found in dierent types of cell adhesion molecules (CAMs), such as the presence of immunoglobulin domains, the presence of a MAM domain or the capacity to anchor to the cell membrane by a GPI motif. Expression analysis in normal human tissues revealed that this gene is expressed as a 5 kb and 9.5 kb mRNA. Furthermore, the smaller transcript is highly expressed in some human cancer cell lines, as well as in dierent primary tumors (lung, colon, uterus, stomach and breast) . Interestingly, the gene was higher expressed in several tumor tissues analysed as compared to their corresponding normal tissues. Thus, GPIM is a novel gene codifying a protein with structural features characteristics of some CAMs, which might be involved in the tumor progression. Oncogene (2002) 21, 3089 ± 3094. DOI: 10.1038/sj/ onc/1205383 Keywords: novel gene; GPI motif; MAM domain; adhesion molecule; cancer Two years ago, we have detected a DNA sequence ampli®ed in non-small-cell lung cancer (NSCLC) by using the AP ± PCR approach (De Juan et al., 1999) . This DNA fragment, called F18, was a 600 bp sequence previously mapped to chromosome 6p12 without any signi®cant homology with known human DNA sequences. Interestingly, survival analysis revealed that disease-free interval of NSCLC patients was shorter in those patients bearing the ampli®ed sequence, suggesting that it might be implicated in the pathogenesis of human lung cancer (De Juan et al., 1999) .
When this study was performed, the region of chromosome 6p closed to F18 had not yet been sequenced. Nevertheless, as the human genome project advanced, clone RP3-402N21 (GenBank accession number AL049553) containing complete F18 sequence, was characterized and mapped to chromosome 6p21. A detailed database analysis of this clone genomic sequence showed several ESTs indicating the existence of a putative novel gene, which included F18 sequence as a part of its ®rst predicted intron. This novel gene predicts a 955-aa protein with a large extracellular region containing an N-terminal signal peptide followed by six immunoglobulin domains, a single ®bronectin type III domain, a MAM domain and a C-terminal signal containing a potential cleavage site for GPI anchoring to the cell membrane. This novel protein is a GPI-anchored protein with a MAM domain in the extracellular region, being the ®rst of such class found until date.
GPI-anchored cell surface glycoproteins are extracellular proteins anchored in the lipid bilayer by GPI instead of membrane-spanning peptides (McConville and Menon, 2000) . Several of these proteins are involved in cell adhesion and subsequent cleavage of the anchor by a speci®c phospholipase or another hydrolase, would be a mechanism for terminating cellcell interaction (Funatsu et al., 1999) . The immunoglobulin superfamily, the largest class of CAMs includes some well characterized GPI-anchored proteins, some of which are implicated in human cancers (Kim et al., 1992; Ilantzis et al., 1997; Peck and Walsh, 1993) . Furthermore, a role in signal transduction had been reported for some GPI anchored proteins (Jones and Varela-Nieto, 1998) . On the other hand, the MAM domain is thought to have an adhesive function, as it is widespread among various adhesive proteins implicated in cell to cell interaction. The receptor tyrosine Figure 1 (a) GPIM nucleotide sequence (8907 bp) and deduced amino acid sequence (955 amino acids) are shown). The putative signal peptide (von Heijne, 1986) including the predicted initiating methionine (Kozak, 1986) (Zondag et al., 1995) .
Taken all together, the two main goals of the present work have been: (i) the molecular characterization of the predicted novel gene which included F18 fragment and (ii) the possible involvement of this gene in lung cancer, as F18 was ®rstly detected in a primary lung cancer, and in other cancer pathologies. Moreover, structural features existing in the predicted protein encoded by the novel GPIM gene, suggests that this protein might be considered as a new cell adhesion molecule.
F18 sequence was tested for similarity to known sequences in the GenBank database using BLAST software (Alstchul et al., 1997; Bairoch et al., 1996) . Database comparison showed total homology of F18 DNA sequence with a fragment of RP3-402N21 clone mapped to human chromosome 6p21.1-21.31. Although F18 had been positioned by us at chromosome 6p12 by radiation hybrid mapping (De Juan et al., 1999) , the location of RP3-402N21 clone at 6p21, and the new human genome database, made us to consider this new position.
Several expressed sequence tags (ESTs) were localized into RP3-402N21 clone by using the NIX programs at the UK Human Genome Mapping Project Resource Centre. An exhaustive analysis of some of these ESTs seems to indicate the existence of a putative gene, which included F18 sequence as a part of its ®rst predicted intron. Full sequences of three IMAGE cDNA clones (2782838, 299088 and 179592) containing the putative gene, were determined. The 8.9 kb cDNA obtained ( Figure 1a ) contains a 2865 nt open reading frame that predicts a 955 aa protein with an estimated molecular mass of 105.8 kDa and a predicted isoelectric point of 8.65. The putative initiator methionine codon lies within a context adequate for translation initiation (Kozak, 1986) . The predicted protein have not been previously described. This novel protein exhibits the structure of a GPI membrane anchored protein with an ectodomain containing an N-terminal signal peptide followed by six immunoglobulin domains, a single ®bronectin type III domain, a MAM (meprin, A5 antigen, protein tyrosine phosphatase m) domain and a C-terminal signal containing a potential cleavage site for GPI membrane anchoring (Figure 1b) . We refer to this protein as GPIM.
GPIM genomic structure was characterized by comparing its 8.9 kb cDNA sequence to human genomic sequence from RP3-402N21 clone. The GPIM gene contains 17 exons and 16 introns, spanning about 65.5 kb of genomic DNA. Exons and intron sizes are shown in Figure 1b . All the intron-exon junctions follow the canonical AG-GT rules (Table 1) . The ®rst exon contains the initiation codon ATG and a 5' UTR of more than 1179 nt (Figure 1 ). The last exon contains a termination codon (TGA) followed by a 4857 nt 3' UTR. The largest intron 1 (32, 638 nt), contains the full F18 sequence. There are two polyadenylation signals: the ®rst one (ATTAAA), at position 4289, contains a mismatch with respect to the consensus (A to T conversion at the second position), a rare variant that is found in less than 10% of the polyadenylation elements (Colgan and Manley, 1997). The second polyadenylation consensus sequence (AA-TAAA) is positioned at 8877. The existence of the two mRNAs was furtherly con®rmed by Northern blot experiments.
To determine the pattern of expression of GPIM, multiple tissue Northern panels containing RNA from normal human tissues and human cancer cell lines were analysed by using dierent probes. As shown Figure  2a , a band corresponding to approximately 9.5 kb was only detected in human brain, while another band of nearly 5 kb was expressed in heart, skeletal muscle and kidney. The same Northern blot was hybridized with a 2 kb 3' UTR probe in order to determinate if the 9.5 kb brain mRNA was due to the use of the second polyadenylation signal. In this case, only the brain mRNA was detected (Figure 2b ). GPIM expression was also detected by RT ± PCR experiments by using RNAs from those human tissues showing a high expression of this gene (results not shown). Sizes of both mRNAs are slightly greater than the GPIM nucleotide sequence (Figure 1 ), suggesting that GPIM transcripts could be extended further 5' from our contig. We further examined GPIM expression in several human cancer cell lines, which allowed us to detect the 5 kb mRNA in nearly all samples, with higher expression levels in melanoma, lymphoblastic leukemia, Burkitt's lymphoma and lung cancer (Figure 2d) .
Analysis of several ESTs with signi®cant homology to the 5 kb mRNA revealed that a high percentage of them had been isolated from dierent types of human cancers: two metastatic melanomas, four lung squamous cell adenocarcinomas, three colon cancers, ®ve germinal cancer cells, one mammary carcinoma, one adrenal gland tumor, one kidney carcinoma, one prostate carcinoma, one uterus carcinoma and two brain cancers. On the other hand, our results revealed that the 9.5 kb mRNA is exclusively detected in human brain. The analysis of ESTs showing total homology to location of F18 sequence as part of the ®rst intron is indicated. ATG and TGA are indicated by vertical bars and the two polyadenylation sites at the last exon, are shown as ®lled triangles. (Lower b) Schematic representation of the GPIM predicted protein domains. Numbers correspond to the amino acids deduced from the cDNA sequence shown in Figure 1a . Arrow indicates the predicted GPI anchoring site at gly 931 . Prediction of protein domains was de®ned by the Pfam database (http:// www.sanger.ac.uk/Software/Pfam/index.shtlm). The potential cleavage site for GPI membrane anchoring was predicted by using the DGPI program (http://members.ncbi.com/_XMCM/jkronegg/unige/GPI-anchor/DGPI_demo-en.html). Ig: immunoglobulin; Fn-III: ®bronectin type III domain; MAM: meprin, A5 antigen, protein tyrosine phosphatase mu; GPI: glycosylphosphatidylinositol this major transcript revealed that most of them had been isolated from human adult and fetal brain, and also from brain cancer. All these ®ndings indicate that the 9.5 kb mRNa seems to be brain speci®c and that the novel gene may be implicated in human cancers. Furthermore, GPIM gene is evolutionary conserved in mammals, as we have found in the GenBank several ESTs expressed in other organisms dierent from human such as: Mus musculus, Rattus norvegicus and Bos taurus, showing high identity to GPIM cDNA sequence.
The mRNA sizes detected in Northern blots are about 500 bp higher than the nucleotide sequence deduced from EST clones. This may be explained, in part, by the size of poly(A) tails detected in Northern mRNAs. Nevertheless this fact is not sucient to explain these dierent sizes. The existence of possible extra internal exons in the GPIM gene have been ruled out by RT ± PCR experiments using dierent primer combinations designed based on the cDNA sequence. In order to determine if the putative ®rst exon was (2); chronic myelogenous leukemia (3); lymphoblastic leukemia (4); Burkitt's lymphoma, Raji (5); colorectal adenocarcinoma (6); lung carcinoma (7); melanoma (8) and (lower panel d) b-actin probe as a control extended further in the 5' direction, 5' RACE experiments were performed. However, these assays have failed probably due to the high GC content present in this region of the gene. We examined expression of GPIM in lung and colorectal cancer tissues and their adjacent normal mucosae by means of Northern blot. Increased expression of GPIM in cancer tissues (T) compared with matched noncancerous tissues (N) was detected in 2 out of 7 colon cancer patients and 3 out of 10 lung cancer patients analysed. Expression of tumor samples was increased 2 ± 4-fold in relation to normal samples (Figure 3a and b) .
GPIM cDNA expression was also analysed in several cancer pathologies (Figure 3c ). High expression of GPIM in tumor samples compared to their corresponding normal tissues was detected in 5 out of 7 uterus tumors (two of them were benign), 3 out of 3 lung carcinomas, 4 out of 8 stomach carcinomas and 2 out of 9 breast carcinomas. The remainder patients showed the same expression in normal and tumoral samples. Only two patients aected by stomach cancer showed a lower expression in T versus N.
All these results revealed that GPIM was frequently overexpressed in tumor tissues compared with their corresponding normal tissues, suggesting that the gene might be involved in tumor progression. As the identi®cation of molecules overexpressed in cancer possess a special interest in order to use them as tumor markers, we are very committed to extend this study to a higher signi®cant group of population in order to obtain strong conclusions.
Based on the GPIM deduced protein, we postulate that this protein may be implicated in cell±cell interaction, as it contains several motifs (immunoglobulin-like domains, ®bronectin type III domain, MAM domain, GPI anchor) that are present among several adhesive molecules (Rao et al., 1992; Beckmann and Bork, 1993) . The immunoglobulin superfamily, the largest class of CAMs, includes some well characterized GPI-anchored proteins. Structurally, Ig molecules have a variable number of Ig motifs and ®bronectin-III repeats in their extracellular domain, and a group of them are anchored in the lipid bilayer by GPI. Some of these proteins are involved in a variety of speci®c cellcell interactions in the developing system, such as LAMP, BIG-1, neuromitrin, CEPU-1, GP55 (Pimenta et al., 1996; Yoshihara et al., 1994; Wilson et al., 1996) . Carcinoembryonic antigen (CEA), CEACAM-6 and neural cell adhesion molecule (NCAM)p125, are adhesion molecules of the Ig superfamily, also GPIlinked to the cell surface and overexpressed in many human cancers (Kim et al., 1992; Ilantzis et al., 1997; Peck and Walsh, 1993) . By the other hand, the MAM domain is thought to have an adhesive function, as it is widespread among various adhesive proteins implicated in cell to cell interactions. This adhesive domain has been recognized in the extracellular region of proteins The 1.9 kb probe from 2782838 clone was used for Northern blot hybridization. b-actin probe was used as control for RNA quality and amount. (c) A Matched Tumor/Normal Expression Array was purchased from Clontech. cDNA expression of GPIM in N and T samples from dierent patients aected by uterus, lung, stomach and breast cancer was analysed by using the same probe described above. (*) indicate increased expression of T sample versus N sample. Ubiquitin probe was used as a control for cDNA amount (results not shown) meprin, A5 antigen and protein tyrosine phosphatase m, k (Beckmann and Bork, 1993; Jiang et al., 1992; Takagi et al., 1991) . It has been reported that MAM domain is necessary for homophilic interactions mediated by receptor tyrosine phosphatases m and k (Zondag et al., 1995) and mediated by neuropilinneuropilin (Chen et al., 1998) . All these proteins containing a MAM domain have a modular receptorlike architecture comprising a signal peptide, an Nterminal extracellular domain, a single transmembrane domain and an intracellular domain. Nevertheless, contrary to all these conventional MAM proteins, the putative GPIM novel protein is a GPI-anchored protein, as it contains a predicted GPI anchoring site (o) at gly 931 followed by an hydro®lic and hydrophobic tail. The presence of these two structural features in the GPIM protein: a MAM domain and GPI anchor, makes it a singular protein, as it is the ®rst of such class described so far. Whether these singular features confer this protein a biological function related to cellular adhesion will be the aim of our future studies.
